首都医科大学学报 ›› 2014, Vol. 35 ›› Issue (2): 194-199.doi: 10.3969/j.issn.1006-7795.2014.02.011

• 精神科基础和临床 • 上一篇    下一篇

重复经颅磁刺激联合帕罗西汀治疗重性抑郁障碍

房萌1, 任艳萍2, 刘辉1, 周方1, 王刚2,3   

  1. 1. 首都医科大学附属北京安定医院三病区, 北京 100088;
    2. 首都医科大学附属北京安定医院, 北京 100088;
    3. 北京脑重大疾病研究院抑郁症研究所, 北京 100088
  • 收稿日期:2014-02-18 出版日期:2014-04-21 发布日期:2014-04-16
  • 基金资助:

    十一五国家科技支撑计划(2007BAI17B05)。

Repetitive transcranial magnetic stimulation in combination with paroxetine for major depressive disorder

Fang Meng1, Ren Yanping2, Liu Hui1, Zhou Fang1, Wang Gang2,3   

  1. 1. 3rd Ward of Beijing Anding Hospital, Capital Medical University, Beijing 100088, China;
    2. Beijing Anding Hospital, Capital Medical University, Beijing 100088, China;
    3. Center of Depression, Beijing Institute for Brain Disorders, Beijing 100088, China
  • Received:2014-02-18 Online:2014-04-21 Published:2014-04-16
  • Contact: 王刚 E-mail:gangwangdoc@gmail.com
  • Supported by:

    This study was supported by National Science and Technology Support Program in 11th Five Year Plan of China(2007BAI17B05).

摘要:

目的 探讨重复经颅磁刺激(repetitive transcranial magnetic stimulation,rTMS)联合帕罗西汀对重性抑郁障碍(major depressive disorder,MDD)的疗效。方法 本研究是一项为期6周的随机、双盲、伪刺激对照临床试验。48例MDD患者采用数字表法随机分为2组接受rTMS真(real)或伪(sham)刺激治疗2周,基线起同时合并固定剂量的帕罗西汀(20 mg/d),rTMS治疗结束后随访至6周末,随访期间帕罗西汀治疗剂量保持不变。设置7个访视点进行疗效评定和不良事件记录。结果 研究结束时,两组患者的蒙哥马利抑郁量表、汉密尔顿抑郁量表17 项、汉密尔顿焦虑量表评分较基线均显著降低,但两组对比总体疗效相当。Real组平均起效时间比Sham组早3天,但差异不具有统计学意义。符合方案人群分析显示Real组对汉密尔顿抑郁量表"焦虑/躯体化"因子分的改善,在第10、14、28天显著优于Sham组;对汉密尔顿焦虑量表评分的改善在第10天显著优于Sham组。2组患者的不良事件发生率差异无统计学意义。结论 rTMS联合帕罗西汀是一种较好的抑郁症治疗方法,显示出较快起效的趋势,rTMS对焦虑症状、躯体化症状可能具有较快的改善作用。

关键词: 重复经颅磁刺激, 重性抑郁障碍, 起效时间

Abstract:

Objective To investigate the efficacy of repetitive transcranial magnetic stimulation(rTMS) in combination with paroxetine for major depressive disorder. Methods In a 6-week, randomized, double-blind, sham-controlled trial, 48 patients with major depressive disorder were randomly assigned to receive real or sham rTMS for 2 weeks. During the 6 weeks, paroxetine was used at a fixed dose of 20 mg per day for all participants. Seven sites were set to conduct assessment of efficacy and adverse events in this study. Results The Montgomery-Asberg Depression Rating(MADRS), the 17-item Hamilton Depression Rating Scale(HAMD-17) and Hamilton Anxiety Rating Scale(HAMA) scores significantly decreased from baseline to the endpoint in both groups. No meaningful difference was observed between the two groups in general clinical effect. The mean time-to-onset was earlier by 3 days in Real group, but the difference was not significant. In the Real group, the scores of HAMD anxiety/somatic symptom factor significantly decreased on day10, 14 and 28; the scores of HAMA significantly decreased on day 10. The incidence of adverse events in both groups had no significant difference. Conclusion The combination of rTMS and paroxetine was effective and safe in treatment of MDD. The tendency of fast onset of effect was observed in the comprehensive intervention, which probably is beneficial to the patients with anxiety and somatic symptoms.

Key words: repetitive transcranial magnetic stimulation, major depressive disorder, time-to-onset

中图分类号: